PS
TEVA icon

Principal Securities’s Teva Pharmaceuticals TEVA Stock Holding History

Principal Securities’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,179
Closed -$84.4K – 3290
2025
Q3 		$84.4K Buy
4,179
+449
+12% +$7.89K ﹤0.01% 1670
2025
Q2 		$62.5K Sell
3,730
-25
-0.7% -$403 ﹤0.01% 1766
2025
Q1 		$82.8K Hold
3,755
– – ﹤0.01% 1524
2024
Q4 		$82.8K Buy
3,755
+271
+8% +$4.93K ﹤0.01% 1518
2024
Q3 		$62.8K Buy
3,484
+224
+7% +$3.92K ﹤0.01% 1592
2024
Q2 		$53K Buy
3,260
+1,705
+110% +$26.3K ﹤0.01% 1599
2024
Q1 		$21.9K Buy
1,555
+528
+51% +$6.66K ﹤0.01% 1963
2023
Q4 		$10.7K Buy
+1,027
New +$9.59K ﹤0.01% 2206

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Principal Securities's TEVA Position: Q4 2025 in Review

Principal Securities sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 4,179 shares — an estimated $84.4K sold.

Principal Securities first reported a position in TEVA in Q4 2023 and held it in 8 quarters. The position peaked at $84.4K in Q3 2025. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Principal Securities reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 4,179 Teva Pharmaceuticals shares in Q4 2025, an estimated $84.4K.
  • Principal Securities first reported a position in Teva Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Teva Pharmaceuticals position peaked at $84.4K in Q3 2025.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.